mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
porcilis pcv m hyo
intervet international b.v. - porcint circovirus typ 2 (pcv2) orf2 subenheten antigen, mycoplasma hyopneumoniae j stam inaktiverade - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar (för gödning) - för aktiv immunisering av svin för att minska viremi, virus fyll i lungorna och lymfoida vävnader, virus sprider orsakas av porcint circovirus typ 2 (pcv2) infektion, och svårighetsgraden av lungcancer skador orsakade av mycoplasma hyopneumoniae infektion. för att minska förlusten av daglig viktökning under avslutningsperioden inför infektioner med mycoplasma hyopneumoniae och / eller pcv2 (som observerats i fältstudier).
porcilis m hyo injektionsvätska, suspension
intervet international b.v. - mycoplasma hyopneumoniae, stam 11, inaktiverad - injektionsvätska, suspension - mycoplasma hyopneumoniae, stam 11, inaktiverad 7 log2 ab-enheter aktiv substans; all-rac-alfa-tokoferylacetat 150 mg adjuvans - mykoplasmavaccin - svin
suvaxyn m hyo vet. injektionsvätska, suspension
fort dodge animal health holland - mycoplasma hyopneumoniae, stam p-5722-3, inaktiverad - injektionsvätska, suspension - mycoplasma hyopneumoniae, stam p-5722-3, inaktiverad 9,3 log10 mhdce aktiv substans; tiomersal hjälpämne; amarant hjälpämne - mykoplasmavaccin - svin
suvaxyn circo+mh rtu
zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inaktiverade virala och inaktiverade bakteriella vacciner - grisar - för aktiv immunisering av grisar från 3 veckors ålder mot svinscirkovirus typ 2 (pcv2) för att minska viral belastning i blod och lymfoida vävnader och fekal avverkning orsakad av infektion med pcv2. för aktiv immunisering av grisar över 3 veckors ålder mot mycoplasma hyopneumoniae för att minska lungskador orsakad av infektion med m. hyopneumoniae.
circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiska medel för suidae - grisar (för gödning) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.
ingelvac m. hyo vet. injektionsvätska, emulsion
boehringer ingelheim danmark a/s - mycoplasma hyopneumoniae, stam j, inaktiverad - injektionsvätska, emulsion - montanide isa 708 1,25 ml adjuvans; mycoplasma hyopneumoniae, stam j, inaktiverad 0,013 antikroppstiter aktiv substans - mykoplasmavaccin - svin
tylan vet. 10 % premix till medicinfoder
elanco gmbh - tylosinfosfat - premix till medicinfoder - 10 % - tylosinfosfat 125 mg aktiv substans - tylosin - svin
fenoflox vet 100 mg/ml injektionsvätska, lösning
chanelle pharmaceuticals manufacturing ltd - enrofloxacin - injektionsvätska, lösning - 100 mg/ml - enrofloxacin 100 mg aktiv substans - enrofloxacin - nöt, svin
denagard vet. 200 mg/ml injektionsvätska, lösning
elanco gmbh - tiamulinvätefumarat - injektionsvätska, lösning - 200 mg/ml - etanol, vattenfri hjälpämne; sesamolja, raffinerad hjälpämne; tiamulinvätefumarat 200 mg aktiv substans - tiamulin - svin